Phytotherapy for Chronic Prostatitis

Overview

Journal Curr Urol Rep

Publisher Current Science

Specialty Urology

Date 2002 Jun 27

PMID 12084332

Citations 2

Authors

F C Lowe

E Fagelman

Affiliations

Soon will be listed here.

Abstract

Chronic prostatitis is a poorly defined condition that is difficult to treat; there are therefore multiple therapies. Although there is a paucity of trials using phytotherapeutic agents, plant extracts have been postulated to have anti-inflammatory effects that might be useful in the treatment of chronic prostatitis. More placebo-controlled trials of longer duration in this condition are needed to ascertain whether there is a significant benefit to the use of phytotherapeutic agents for chronic prostatitis.

Citing Articles

The management of chronic prostatitis in men with HIV.

Santillo V, Lowe F Curr Urol Rep. 2006; 7(4):313-9.

PMID: 16930503 DOI: 10.1007/s11934-996-0011-3.

Complementary and alternative medicine for chronic prostatitis/chronic pelvic pain syndrome.

Capodice J, Bemis D, Buttyan R, Kaplan S, Katz A Evid Based Complement Alternat Med. 2005; 2(4):495-501.

PMID: 16322807 PMC: 1297501. DOI: 10.1093/ecam/neh128.

References

Lowe F, Fagelman E . Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Urology. 1999; 53(4):671-8. DOI: 10.1016/s0090-4295(98)00664-5. View

Rhodes L, Primka R, BERMAN C, Vergult G, Gabriel M, Gibelin B . Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate. 1993; 22(1):43-51. DOI: 10.1002/pros.2990220107. View

Sultan C, Terraza A, Devillier C, Carilla E, Briley M, Loire C . Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts. J Steroid Biochem. 1984; 20(1):515-9. DOI: 10.1016/0022-4731(84)90264-4. View

Buck A . Phytotherapy for the prostate. Br J Urol. 1996; 78(3):325-36. DOI: 10.1046/j.1464-410x.1996.00104.x. View

Strauch G, PERLES P, Vergult G, Gabriel M, Gibelin B, Cummings S . Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol. 1994; 26(3):247-52. DOI: 10.1159/000475388. View

Mencia Huerta J, Cousse H, Braquet P . Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997; 57(3):299-304. DOI: 10.1016/s0952-3278(97)90548-2. View

Bach D, Walker H . How important are prostaglandins in the urology of man?. Urol Int. 1982; 37(3):160-71. DOI: 10.1159/000280813. View

Levin R, Riffaud J, Bellamy F, Rohrmann D, Krasnopolsky L, HAUGAARD N . Effects of tadenan pretreatment on bladder physiology and biochemistry following partial outlet obstruction. J Urol. 1996; 156(6):2084-8. View

Shoskes D, Zeitlin S, Shahed A, Rajfer J . Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology. 1999; 54(6):960-3. DOI: 10.1016/s0090-4295(99)00358-1. View

10.

Loschen G, Ebeling L . [Inhibition of arachidonic acid cascade by extract of rye pollen]. Arzneimittelforschung. 1991; 41(2):162-7. View

11.

RUGENDORFF E, Weidner W, Ebeling L, Buck A . Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia. Br J Urol. 1993; 71(4):433-8. DOI: 10.1111/j.1464-410x.1993.tb15988.x. View

12.

Levin R, Riffaud J, Bellamy F, Rohrmann D, Habib M, Krasnopolsky L . Protective effect of Tadenan on bladder function secondary to partial outlet obstruction. J Urol. 1996; 155(4):1466-70. View

13.

Bruchovsky N . Comparison of the metabolites formed in rat prostate following the in vivo administration of seven natural androgens. Endocrinology. 1971; 89(5):1212-22. DOI: 10.1210/endo-89-5-1212. View

14.

Buck A, Rees R, Ebeling L . Treatment of chronic prostatitis and prostatodynia with pollen extract. Br J Urol. 1989; 64(5):496-9. DOI: 10.1111/j.1464-410x.1989.tb05285.x. View

15.

Zahradnik H, Schillfahrt R, Schoening R, EBBINGHAUS K, Dunzendorfer U . [Prostaglandin content in prostatic adenomas after treatment with a sterol]. Fortschr Med. 1980; 98(2):(69)-(72). View

16.

Iehle C, Delos S, Guirou O, Tate R, Raynaud J, Martin P . Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors. J Steroid Biochem Mol Biol. 1995; 54(5-6):273-9. DOI: 10.1016/0960-0760(95)00134-l. View

17.

Rolland P, Martin P, Serment G, Roulier R, Rolland A . Human benign prostatic hypertrophy: role of prostaglandin E2 and its relationships to bromocriptine therapy. Eur Urol. 1981; 7(1):41-5. DOI: 10.1159/000473171. View

18.

Lowe F, Ku J . Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology. 1996; 48(1):12-20. DOI: 10.1016/s0090-4295(96)00077-5. View